News & Analysis as of

Misbranding

Epstein Becker & Green

Is Your Product Ready to Be Listed? What the Dietary Supplement Listing Act of 2026 Means for Your Business

Epstein Becker & Green on

The Dietary Supplement Listing Act of 2026 (H.R. 8370, 119th Congress) (the “Act”), introduced in the U.S. House of Representatives on April 20, 2026, has the potential to significantly impact the dietary supplement industry....more

Stevens & Lee

Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement

Stevens & Lee on

There has been a recent and sudden uptick in enforcement from federal agencies against medspa prescribers. Specifically, the Department of Justice (DOJ) recently indicted a licensed osteopathic physician for allegedly...more

Arnall Golden Gregory LLP

You Oughta Know: Companies Should Pay Attention When OPDP Drops a Warning Letter

Key Takeaways - The Food and Drug Administration is increasing enforcement of direct-to-consumer drug promotion, with a recent Warning Letter citing misleading claims, inadequate risk disclosure, and promotion beyond approved...more

Shook, Hardy & Bacon L.L.P.

Food and Beverage Litigation and Regulatory Update - March 2026

Denial of a motion to dismiss a "cage free" eggs lawsuit, updates on marketing plant-based products with meat- and dairy-related terms in Europe, dismissal of a lawsuit alleging a restaurant's salsa was excessively spicy, and...more

Foley & Lardner LLP

GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters

Foley & Lardner LLP on

On March 3, 2026, U.S. Food & Drug Administration (FDA) sent 30 warning letters to telehealth companies that market compounded GLP‑1 products. These letters highlight FDA’s current enforcement priorities in the compounded...more

Sheppard

A “New Era” of Consumer Medicine? FDA Takes Another Swipe at “Unapproved” Compounded Drugs

Sheppard on

For years, the commercial compounding and telehealth industry blossomed, buoyed by exploding consumer interest in GLP-1s and other compounded drugs. But things are changing. We recently blogged more generally about the...more

Cozen O'Connor

FDA’s Enforcement Discretion Over “No Artificial Color” Claims

Cozen O'Connor on

On February 5, 2026, the Food and Drug Administration (FDA) took another step to incentivize manufacturers to comply with the administration’s efforts to phase-out artificial petroleum-based color additives from the nation’s...more

Skadden, Arps, Slate, Meagher & Flom LLP

FDA’s New Enforcement Discretion on ‘No Artificial Colors’ Claims: Implications and Risks for Food Manufacturers

On February 5, 2026, the Food and Drug Administration (FDA) announced a significant shift in its enforcement approach to voluntary labeling claims regarding artificial colors in foods....more

Haynes Boone

FDA Takes Steps to Ease Path for Non-Petroleum Food Colors

Haynes Boone on

After years of maintaining a policy that any added color in food is “artificial color,” the U.S. Food and Drug Administration (FDA) issued a letter to industry announcing that it will exercise enforcement discretion as to the...more

Ropes & Gray LLP

FDA Enforcement Review: Looking Back at 2025 and Bracing for Continued Unpredictability in 2026

Ropes & Gray LLP on

In 2025, the U.S. Food and Drug Administration (“FDA”) and U.S. Department of Justice (“DOJ”) pursued significant criminal, civil, and regulatory enforcement actions grounded in longstanding enforcement priorities across...more

Alston & Bird

For Your Consumption | November 2025: Ain’t No Rest for the Plaintiffs

Alston & Bird on

In the November edition of For Your Consumption, our food & beverage digest of court cases and litigation trends affecting the food, beverage, agribusiness, and cosmetics industries, a plaintiff is choking on the splinters,...more

Lowenstein Sandler LLP

Federal Court Blocks DOJ Subpoena Targeting Gender-Affirming Care Records

Lowenstein Sandler LLP on

The Department of Justice’s (DOJ) initial attempts to carry out the White House’s goal of eliminating gender-affirming health care to minors have hit substantial roadblocks. As one example, a federal court in Massachusetts...more

Holland & Knight LLP

FDA, HHS Taking Action Against Telehealth's Compounded Drug Advertising

Holland & Knight LLP on

The U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services (HHS) on Sept. 9, 2025, announced a broad initiative to "rein in misleading direct-to-consumer pharmaceutical advertisements." In...more

Sheppard

What to Watch: WHOOP Warning Letter

Sheppard on

On July 14, the U.S. Food and Drug Administration (“FDA” or the “Agency”) issued a warning letter (the “Warning Letter”) to WHOOP, Inc. (“WHOOP”), rejecting WHOOP’s claim that its wearable “Blood Pressure Insights” product...more

Perkins Coie

Food & Consumer Packaged Goods Litigation 2024 | YEAR IN REVIEW

Perkins Coie on

Perkins Coie Releases Ninth Annual Food & Consumer Packaged Goods Litigation Year in Review. In 2024, class action filings against the consumer packaged goods (CPG) industry reached a near high, with close to three hundred...more

Polsinelli

Monday Morning (Advertising) Quarterback – Unprecedented Hims & Hers Super Bowl Ad Has Legislators Concerned

Polsinelli on

The Super Bowl is not just the biggest game of the year for football fans, but it is also one of advertising’s biggest nights. Therefore, the FDA lawyers at Polsinelli were not only tuned in to root for the Kansas City Chiefs...more

A&O Shearman

Consulting Firm Agrees To Pay $650 Million In A Deferred Prosecution Agreement

A&O Shearman on

On December 13, 2024, the United States Attorney’s Offices for the Western District of Virginia and the District of Massachusetts, along with the Department of Justice’s (“DOJ”) Consumer Protection Branch (collectively, “the...more

Cozen O'Connor

AGs Urge EPA to Adopt Rule Preempting State Labeling Requirements

Cozen O'Connor on

Eleven Republican AGs filed a petition for rulemaking to the EPA demanding that it amend its regulations under the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”) regarding additional labeling or packaging...more

Rivkin Radler LLP

The Case of ‘Gas Station Heroin’

Rivkin Radler LLP on

Is It Necessary for Congress to Amend the FD&C Act for FDA to Have the Authority to Prohibit Tianeptine’s Sale? If the answer to this question is “no,” why are bills being introduced into Congress to give the U.S. Food and...more

Kaufman & Canoles

K&C Sports & Entertainment Law Weekly Roundup - June 2024 #2

Kaufman & Canoles on

Game equipment company Sport Squad Inc. deceptively marketed some of its pickleball paddles as approved by the sport’s national governing body even though the approval had been rescinded, a consumer class action alleges....more

Morrison & Foerster LLP

Implied Preemption for Dietary Supplements Is Here to Stay

On April 15, 2024, in a big win for the continued validity of implied preemption, the Supreme Court declined to hear an appeal of the First Circuit’s preemption-based dismissal of a proposed misbranding class action. The...more

Mitchell, Williams, Selig, Gates & Woodyard,...

FIFRA Enforcement: US Environmental Protection Agency and Paris, Missouri Pesticide Dealer Enter into Consent Agreement

The United States Environmental Protection Agency (“EPA”) and Logan Agride – Service, Inc (“Logan”) entered into an April 15th Consent Agreement and Final Order (“CAFO”) addressing alleged violations of the Federal...more

Arnall Golden Gregory LLP

Every Little One, Every Little One: FDA Issues a Warning Letter to a Medical Device Reprocessor for Changes to Marketed Products

“Every little one, every little one,” a song lyric from Bruce Hornsby and the Range’s 1986 single, “Every Little Kiss,” comes to mind when we read a recent Food and Drug Administration Warning Letter issued to a reprocessor...more

Fishman Haygood LLP

U.S. Eleventh Circuit Rejects FIFRA Preemption in Roundup Case

Fishman Haygood LLP on

As of May 2022, Monsanto, the company that developed the allegedly cancer-causing weed killer Roundup, has settled more than 100,000 lawsuits, and paid nearly $11 billion in settlements. Despite this massive number, 30,000...more

Epstein Becker & Green

Podcast: Dietary Supplements – Navigating the Regulatory Maze – Diagnosing Health Care

Epstein Becker & Green on

The U.S. Food and Drug Administration’s (FDA’s) broad definition of “misbranding” has created some industry confusion, while the Federal Trade Commission’s (FTC’s) updates to its Health Products Compliance Guidance have done...more

156 Results
 / 
View per page
Page: of 7

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide